MedPath

Safety Evaluation of Topical Application of Nano-Liposomal Amphotericin B (Sinaampholeish)

Phase 1
Conditions
Cutaneous leishmaniasis.
Cutaneous leishmaniasis
Registration Number
IRCT20081130001475N12
Lead Sponsor
eglected Diseases Initiative
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
27
Inclusion Criteria

Healthy volunteer
aged between 18-65
willingness to participate in the study and signing the informed consent form

Exclusion Criteria

Any disease or illness according to subject history
Mentally ill based on physician diagnosis
participating in other concurrent trial

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Erythema. Timepoint: Daily evaluation after the 1st day of intervention to 7th day. Method of measurement: clinical exam.;Pruritus. Timepoint: Daily evaluation after the 1st day of intervention to 7th day. Method of measurement: clinical Exam.
Secondary Outcome Measures
NameTimeMethod
Any reported adverse events. Timepoint: Daily evaluation after the 1st day of intervention to 7th day. Method of measurement: Participants history.
© Copyright 2025. All Rights Reserved by MedPath